Page 54 - ஜப்பான் அமைச்சகம் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan Font : A-A+ from Treatment with Lynparza More Than 20,000 Patients in Japan Now Qualify for Genetic Testing SALT LAKE CITY, Jan. 19, 2021 (GLOBE NEWSWIRE) In an announcement that will help more people with advanced prostate and pancreatic cancers in Japan, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will receive reimbursement for its BRACAnalysis ® Diagnostic System, which helps physicians determine whether certain patients will qualify and potentially benefit from treatment with the PARP inhibitor, Lynparza (olaparib). BRACAnalysis was approved by Japan’s Ministry of Health, Labour and Welfare (MHLW) in October 2020 as a companion diagnostic for these indications and the reimbursement decision is now in effect.

United statesHideki uenoJared maxwellBracanalysis cdxScott gleasonNicole lambertHiroji uemuraHu group holdings incTsrl incBank intlMerck co incYokohama city university medical centerInternational agency for research on cancerJapan ministry of healthNational cancer center hospitalWorld health organization